Juno Therapeutics ($JUNO) received a positive judgement from the US Patent & Trademark Office (USPTO) regarding its US Patent No. 7,446,190. The case was filed by Kite Pharmaceuticals which seek to invalidate the patent. It has challenged all of the company’s claims to the patent. The patent is titled “Nucleic Acids Encoding Chimeric T Cell Receptors.” It is exclusively licenses by Juno from Sloan Kettering Institute for Cancer Research, an affiliate of Memorial Sloan Kettering Cancer Center.
USPTO issued its final written decision on December 16, 2016, which upheld all the claims of the patent. Juno Therapeutics focuses on developing treatments related to the body’s immune system.